Stockscreener 앱 받기
94.31
2.53%
2.33
시간 외 거래:
94.31
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Rhythm Pharmaceuticals Inc. Forms Bullish Flag — Upside AheadSmart Allocation Stock Pick Insights Gaining Interest - beatles.ru
Rhythm Pharmaceuticals: Unlocking Value as Key Lock-Up Expiry and Setmelanotide Regulatory Milestones Loom - AInvest
Rhythm Pharmaceuticals and the Impending Lock-Up Expiry: A Catalyst for Shareholder Value Realization - AInvest
Rhythm Pharmaceuticals: A Post-Lock-Up Opportunity with Strong Catalysts in Q3 2025 and Beyond - AInvest
Rhythm Pharmaceuticals Lock-Up Agreement Ends on August 9, 2025 - AInvest
Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight | VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski - The Globe and Mail
12 Analysts Weigh In on Rhythm Pharmaceuticals: A Comprehensive Analysis of Ratings and Price Targets - AInvest
Rhythm Pharmaceuticals Exceeds Q2 Expectations, Maintains Buy Rating - AInvest
Leerink Partners Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals - TipRanks
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals stock price target raised to $100 from $80 at H.C. Wainwright - Investing.com Canada
HC Wainwright Raises PT to $100, Maintains Buy Rating on Rhythm Pharmaceuticals. - AInvest
Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - Yahoo Finance
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating - TipRanks
Guggenheim Raises Rhythm Pharmaceuticals Buy Rating, PT to $120 - AInvest
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - MSN
Citizens JMP raises Rhythm Pharmaceuticals stock price target to $135 on growth - Investing.com Canada
Rhythm Pharmaceuticals shares rise 3.30% premarket after reporting Q2 2025 earnings. - AInvest
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highligh - GuruFocus
Rhythm Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Rhythm Pharmaceuticals Q2 Revenue Surpasses Estimates, Up 67% YoY - AInvest
Rhythm Pharmaceuticals Achieves 29% QoQ Revenue Growth, Sets Sights on HO Regulatory Filings - AInvest
Rhythm Pharmaceuticals' Q2 2025: Navigating Key Contradictions in Trial Design, Stock Compensation, and Market Dynamics - AInvest
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $95 - 富途牛牛
Rhythm Pharmaceuticals stock price target raised to $110 from $85 at TD Cowen - Investing.com Canada
Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley - TipRanks
Rhythm Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating - TipRanks
Rhythm Pharmaceuticals Q2 2025 slides: Revenue jumps 29%, obesity drugs show promise - Investing.com Canada
Rhythm Pharmaceuticals Fiscal Q2 Net Loss Widens, Revenue Rises - MarketScreener
Rhythm Pharmaceuticals Q2 revenue up 67% yr/yr, net loss widens - MarketScreener
Rhythm Pharmaceuticals Reports Q2 GAAP EPS of -$0.75, Revenue at $48.5 Million - AInvest
Rhythm Pharmaceuticals enrolls first patient in Part C of Phase 1 RM-718 trial - TipRanks
Rhythm Pharmaceuticals Q2 2025 Financial Results and Business Update - TradingView
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Rhythm Pharmaceuticals Q2 net product revenue $48.5mln, raises $189.2mln. - AInvest
Rhythm Pharmaceuticals to Discuss Q2 Financial Results and Corporate Updates on August 5, 2025 - AInvest
How strong is Rhythm Pharmaceuticals Inc. company’s balance sheetDiscover top stock picks for aggressive growth - Jammu Links News
How does Rhythm Pharmaceuticals Inc. generate profit in a changing economyHigh-margin investment plays - Jammu Links News
What are the latest earnings results for Rhythm Pharmaceuticals Inc.Free Investment Timing Strategies - Jammu Links News
Is it the right time to buy Rhythm Pharmaceuticals Inc. stockAchieve breakthrough financial results today - Jammu Links News
Does Rhythm Pharmaceuticals Inc. stock perform well during market downturnsRapid wealth multiplication - Jammu Links News
Is Rhythm Pharmaceuticals Inc. stock overvalued or undervaluedRecord-breaking gains - Jammu Links News
How does Rhythm Pharmaceuticals Inc. compare to its industry peersGet exclusive access to expert stock recommendations - Jammu Links News
What are Rhythm Pharmaceuticals Inc. company’s key revenue driversMaximize your gains with professional insights - Jammu Links News
Why is Rhythm Pharmaceuticals Inc. stock attracting strong analyst attentionAchieve rapid financial growth with expert help - Jammu Links News
Should I hold or sell Rhythm Pharmaceuticals Inc. stock in 2025Uncover the best stocks for explosive growth - Jammu Links News
When is Rhythm Pharmaceuticals Inc. stock expected to show significant growthRapid wealth creation - Jammu Links News
Rhythm Pharmaceuticals shares rise 2.48% intraday after Ligand and Medtronic's $70 million investment in Orchestra BioMed. - AInvest
Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM) - Insider Monkey
Rhythm pharmaceuticals exec Cramer sells $130k in shares By Investing.com - Investing.com India
Cramer, Rhythm Pharmaceuticals’ CHRO, sells $130k in shares By Investing.com - Investing.com Canada
1.02%
3.70%
자본화:
|
볼륨(24시간):